# Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration

> **NCT00395707** · PHASE1,PHASE2 · COMPLETED · sponsor: **The National Retina Institute** · enrollment: 20 (estimated)

## Conditions studied

- Macular Degeneration

## Interventions

- **DRUG:** Lucentis
- **DRUG:** Ranibizumab
- **DRUG:** Ranibizumab (Lucentis)
- **DRUG:** Ranibizumab (Lucentis)

## Key facts

- **NCT ID:** NCT00395707
- **Lead sponsor:** The National Retina Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2008-04
- **Final completion:** 2008-04
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2009-02-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00395707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00395707, "Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00395707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*